GDC-0941 activates integrin linked kinase (ILK) expression to cause resistance to GDC-0941 in breast cancer by the tumor necrosis factor (TNF)-α signaling pathway

References

• Lovelace DL, McDaniel LR, Golden D. Long-term effects of breast cancer surgery, treatment, and survivor care. J Midwifery Womens Health. 2019;64(6):713–724.
   PubMed Web of Science ®Google Scholar
• Zheng R, Zeng H, Zhang S, et al. Estimates of cancer incidence and mortality in China, 2013. Chin J Cancer. 2017;36(1):66.
   PubMedGoogle Scholar
• El Sayed R, El Jamal L, El Iskandarani S, et al. Endocrine and targeted therapy for hormone-receptor-positive, HER2-negative advanced breast cancer: insights to sequencing treatment and overcoming resistance based on clinical trials. Front Oncol. 2019;9:510.
   PubMed Web of Science ®Google Scholar
• Dey N, De P, Leyland-Jones B. PI3K-AKT-mTOR inhibitors in breast cancers: from tumor cell signaling to clinical trials. Pharmacol Ther. 2017;175:91–106.
   PubMed Web of Science ®Google Scholar
• Burrows N, Babur M, Resch J, et al. GDC-0941 inhibits metastatic characteristics of thyroid carcinomas by targeting both the phosphoinositide-3 kinase (PI3K) and hypoxia-inducible factor-1alpha (HIF-1alpha) pathways. J Clin Endocrinol Metab. 2011;96(12):E1934–43.
   PubMed Web of Science ®Google Scholar
• Zheng L, Yang W, Zhang C, et al. GDC-0941 sensitizes breast cancer to ABT-737 in vitro and in vivo through promoting the degradation of Mcl-1. Cancer Lett. 2011;309(1):27–36.
   PubMed Web of Science ®Google Scholar
• Zou ZQ, Zhang LN, Wang F, et al. The novel dual PI3K/mTOR inhibitor GDC-0941 synergizes with the MEK inhibitor U0126 in non-small cell lung cancer cells. Mol Med Rep. 2012;5(2):503–508.
   PubMed Web of Science ®Google Scholar
• García-Martínez JM, Wullschleger S, Preston G, et al. Effect of PI3K- and mTOR-specific inhibitors on spontaneous B-cell follicular lymphomas in PTEN/LKB1-deficient mice. Br J Cancer. 2011;104(7):1116–1125.
   PubMed Web of Science ®Google Scholar
• Raynaud FI, Eccles SA, Patel S, et al. Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941. Mol Cancer Ther. 2009;8(7):1725–1738.
   PubMed Web of Science ®Google Scholar
• Munugalavadla V, Mariathasan S, Slaga D, et al. The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma. Oncogene. 2014;33(3):316–325.
   PubMed Web of Science ®Google Scholar
• Shi L, Gao X, Li X, et al. Ellagic acid enhances the efficacy of PI3K inhibitor GDC-0941 in breast cancer cells. Curr Mol Med. 2015;15(5):478–486.
   PubMed Web of Science ®Google Scholar
• El Kharbili M, Robert C, Witkowski T, et al. Tetraspanin 8 is a novel regulator of ILK-driven beta1 integrin adhesion and signaling in invasive melanoma cells. Oncotarget. 2017;8(10):17140–17155.
   PubMedGoogle Scholar
• Rooney N, Wang P, Brennan K, et al. The integrin-mediated ILK-Parvin-alphaPix signaling axis controls differentiation in mammary epithelial cells. J Cell Physiol. 2016;231(11):2408–2417.
   PubMed Web of Science ®Google Scholar
• Fazli L, Costello P, Sutton K, et al. Regulation of tumor angiogenesis by integrin-linked kinase (ILK). Cancer Cell. 2004;5(1):79–90.
   PubMed Web of Science ®Google Scholar
• Li G, Li YY, Sun JE, et al. ILK-PI3K/AKT pathway participates in cutaneous wound contraction by regulating fibroblast migration and differentiation to myofibroblast. Lab Invest. 2016;96(7):741–751.
   PubMed Web of Science ®Google Scholar
• Jurisic V. Multiomic analysis of cytokines in immuno-oncology. Expert Rev Proteomics. 2020;17(9):663–674.
   PubMed Web of Science ®Google Scholar
• Chou CK, Chen RF, Chou FF, et al. miR-146b is highly expressed in adult papillary thyroid carcinomas with high risk features including extrathyroidal invasion and the BRAF(V600E) mutation. Thyroid. 2010;20(5):489–494.
   PubMed Web of Science ®Google Scholar
• Yau CY, Wheeler JJ, Sutton KL, et al. Inhibition of integrin-linked kinase by a selective small molecule inhibitor, QLT0254, inhibits the PI3K/PKB/mTOR, Stat3, and FKHR pathways and tumor growth, and enhances gemcitabine-induced apoptosis in human orthotopic primary pancreatic cancer xenografts. Cancer Res. 2005;65(4):1497–1504.
   PubMed Web of Science ®Google Scholar
• Wang LC. Mass spectrometry-based proteomic analysis of inhibitor of kappa B kinase beta and its role in cytokine-induced drug resistance in cancer. Dissertations & Theses - Gradworks. 2007;105(1):119–124.
   Google Scholar
• Zhai Z, Mu T, Zhao L, et al. MiR-181a-5p facilitates proliferation, invasion, and glycolysis of breast cancer through NDRG2-mediated activation of PTEN/AKT pathway. Bioengineered. 2022;13(1):83–95.
   PubMed Web of Science ®Google Scholar
• Wallin JJ, Guan J, Prior WW, et al. GDC-0941, a novel class I selective PI3K inhibitor, enhances the efficacy of docetaxel in human breast cancer models by increasing cell death in vitro and in vivo. Clin Cancer Res. 2012;18(14):3901–3911.
   PubMed Web of Science ®Google Scholar
• Maira SM, Pecchi S, Huang A, et al. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol Cancer Ther. 2012;11(2):317–328.
   PubMed Web of Science ®Google Scholar
• Qiu Z, Zhou B, Jin L, et al. In vitro antioxidant and antiproliferative effects of ellagic acid and its colonic metabolite, urolithins, on human bladder cancer T24 cells. Food Chem Toxicol. 2013;59:428–437.
   PubMed Web of Science ®Google Scholar
• Becker MA, Djcr Y. IGF-I mediated phosphorylation of ER S167 occurs downstream of mTOR/p70S6K1 to impact nuclear localization and chromatin interaction. Cancer Res. 2009;69(2 Supplement):6012.
   Web of Science ®Google Scholar
• Wu Y, Chen W, Gong Y, et al. Tetraspanin 1 (TSPAN1) promotes growth and transferation of breast cancer cells via mediating PI3K/Akt pathway. Bioengineered. 2021;12(2):10761–10770.
   PubMed Web of Science ®Google Scholar
• Coffer PJ, Jin J, Jrjbj W. Protein kinase B (c-Akt): a multifunctional mediator of phosphatidylinositol 3-kinase activation. The Biochemical Journal. 1998;335(1):1–13. Pt 1.
   PubMed Web of Science ®Google Scholar
• Delcommenne M, Tan C, Gray V, et al. Phosphoinositide-3-OH kinase-dependent regulation of GSK-3 and PKB/AKT by the integrin-linked kinase. Proceedings of the National Academy of Sciences of the United States of America. 1998;95(19):11211–11216.
   PubMed Web of Science ®Google Scholar
• Xia P, Xu XY. PI3K/Akt/mTOR signaling pathway in cancer stem cells: from basic research to clinical application. Am J Cancer Res. 2015;5(5):1602–1609.
   PubMed Web of Science ®Google Scholar
• Dedhar S. Cell-substrate interactions and signaling through ILK. Curr Opin Cell Biol. 2000;12(2):250–256.
   PubMed Web of Science ®Google Scholar
• Yoganathan TN, Costello P, Chen X, et al. Integrin-linked kinase (ILK): a “hot” therapeutic target. Biochem Pharmacol. 2000;60(8):1115–1119.
   PubMed Web of Science ®Google Scholar